Cargando…
Skeletal Metastases in Pancreatic Cancer: A Retrospective Study and Review of the Literature
Background: Skeletal metastases represent an underappreciated site of metastasis in patients with pancreatic cancer. Previous reports have estimated the prevalence to range from 5 percent to 20 percent. With the use of gemcitabine and novel targeted agents such as erlotinib, there has been a modest...
Autores principales: | Borad, Mitesh J., Saadati, Hamid, Lakshmipathy, Arun, Campbell, Elizabeth, Hopper, Patricia, Jameson, Gayle, Von Hoff, Daniel D., Saif, M. Wasif |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Yale Journal of Biology and Medicine
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2660584/ https://www.ncbi.nlm.nih.gov/pubmed/19325940 |
Ejemplares similares
-
Marantic Endocarditis Associated with Pancreatic Cancer: A Case Series
por: Jameson, Gayle S., et al.
Publicado: (2009) -
The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials
por: Borad, Mitesh J., et al.
Publicado: (2012) -
Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases
por: Saif, Muhammad Wasif
Publicado: (2014) -
Pancreatic Tuberculosis or Autoimmune Pancreatitis
por: Salahuddin, Ayesha, et al.
Publicado: (2014) -
(18)F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer
por: Korn, Ronald L., et al.
Publicado: (2017)